DZ2314A1 - Formulation pour administration par voie orale à libération immédiate retardée et procédé pour sa préparation. - Google Patents

Formulation pour administration par voie orale à libération immédiate retardée et procédé pour sa préparation.

Info

Publication number: DZ2314A1
Authority: DZ; Algeria
Prior art keywords: immediate release; compounds; release formulation; delayed immediate; oral delayed
Prior art date: 1996-09-23

Application number

DZ970164A

Other languages

English (en)

French (fr)

Inventor

Jules Alex Cornelis Elbers

Henderik Willem Frijlink

Wienman Emerald Philips

Balken Paulus Maria Van

Original Assignee

Duphar Int Res

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-09-23

Filing date

1997-09-22

Publication date

2002-12-28

1997-09-22 Application filed by Duphar Int Res filed Critical Duphar Int Res

2002-12-28 Application granted granted Critical

2002-12-28 Publication of DZ2314A1 publication Critical patent/DZ2314A1/xx

Links

239000012729 immediate-release (IR) formulation Substances 0.000 title abstract 8
230000003111 delayed effect Effects 0.000 title abstract 6
238000009472 formulation Methods 0.000 title abstract 3
239000000203 mixture Substances 0.000 title abstract 3
238000000034 method Methods 0.000 title abstract 2
150000001875 compounds Chemical class 0.000 abstract 7
239000013543 active substance Substances 0.000 abstract 3
230000003110 anti-inflammatory effect Effects 0.000 abstract 2
239000011248 coating agent Substances 0.000 abstract 2
238000000576 coating method Methods 0.000 abstract 2
230000002496 gastric effect Effects 0.000 abstract 2
206010002383 Angina Pectoris Diseases 0.000 abstract 1
229940123907 Disease modifying antirheumatic drug Drugs 0.000 abstract 1
102000004190 Enzymes Human genes 0.000 abstract 1
108090000790 Enzymes Proteins 0.000 abstract 1
108091034117 Oligonucleotide Proteins 0.000 abstract 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
230000000202 analgesic effect Effects 0.000 abstract 1
230000000049 anti-anxiety effect Effects 0.000 abstract 1
230000002456 anti-arthritic effect Effects 0.000 abstract 1
230000001088 anti-asthma Effects 0.000 abstract 1
230000001430 anti-depressive effect Effects 0.000 abstract 1
230000003474 anti-emetic effect Effects 0.000 abstract 1
230000003276 anti-hypertensive effect Effects 0.000 abstract 1
230000003356 anti-rheumatic effect Effects 0.000 abstract 1
230000000767 anti-ulcer Effects 0.000 abstract 1
230000001362 anti-vertigo Effects 0.000 abstract 1
239000000924 antiasthmatic agent Substances 0.000 abstract 1
239000000935 antidepressant agent Chemical class 0.000 abstract 1
229940005513 antidepressants Drugs 0.000 abstract 1
239000002111 antiemetic agent Substances 0.000 abstract 1
229940125683 antiemetic agent Drugs 0.000 abstract 1
239000002220 antihypertensive agent Chemical class 0.000 abstract 1
229940030600 antihypertensive agent Drugs 0.000 abstract 1
239000003435 antirheumatic agent Substances 0.000 abstract 1
239000002249 anxiolytic agent Chemical class 0.000 abstract 1
239000000496 cardiotonic agent Substances 0.000 abstract 1
230000003177 cardiotonic effect Effects 0.000 abstract 1
239000000969 carrier Substances 0.000 abstract 1
239000003246 corticosteroid Substances 0.000 abstract 1
229960001334 corticosteroids Drugs 0.000 abstract 1
239000012530 fluid Substances 0.000 abstract 1
102000004196 processed proteins & peptides Human genes 0.000 abstract 1
108090000765 processed proteins & peptides Proteins 0.000 abstract 1
102000004169 proteins and genes Human genes 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 abstract 1
239000000932 sedative agent Chemical class 0.000 abstract 1
229940125723 sedative agent Drugs 0.000 abstract 1
230000002522 swelling effect Effects 0.000 abstract 1
229960005486 vaccine Drugs 0.000 abstract 1
229940124549 vasodilator Drugs 0.000 abstract 1
239000003071 vasodilator agent Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Virology (AREA)
Pulmonology (AREA)
Mycology (AREA)
Microbiology (AREA)
Immunology (AREA)
Cardiology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Neurosurgery (AREA)
Heart & Thoracic Surgery (AREA)
Rheumatology (AREA)
Anesthesiology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Cosmetics (AREA)

DZ970164A 1996-09-23 1997-09-22 Formulation pour administration par voie orale à libération immédiate retardée et procédé pour sa préparation. DZ2314A1 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP96202651		1996-09-23

Publications (1)

Publication Number	Publication Date
DZ2314A1 true DZ2314A1 (fr)	2002-12-28

Family

ID=8224414

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DZ970164A DZ2314A1 (fr)	1996-09-23	1997-09-22	Formulation pour administration par voie orale à libération immédiate retardée et procédé pour sa préparation.

Country Status (29)

Country	Link
US (1)	US6183780B1 (cs)
EP (1)	EP0939623B1 (cs)
JP (1)	JP4947824B2 (cs)
KR (1)	KR100501966B1 (cs)
CN (1)	CN1161110C (cs)
AT (1)	ATE213627T1 (cs)
AU (1)	AU717711B2 (cs)
BR (1)	BR9711303A (cs)
CA (1)	CA2263921C (cs)
CZ (1)	CZ294641B6 (cs)
DE (1)	DE69710756T2 (cs)
DK (1)	DK0939623T3 (cs)
DZ (1)	DZ2314A1 (cs)
ES (1)	ES2172003T3 (cs)
HR (1)	HRP970493A2 (cs)
HU (1)	HU226693B1 (cs)
ID (1)	ID22039A (cs)
IL (1)	IL128565A (cs)
JO (1)	JO2066B1 (cs)
NO (1)	NO325763B1 (cs)
NZ (1)	NZ334463A (cs)
PL (1)	PL189016B1 (cs)
PT (1)	PT939623E (cs)
RU (1)	RU2193395C2 (cs)
SK (1)	SK284263B6 (cs)
TR (1)	TR199900641T2 (cs)
UA (1)	UA72182C2 (cs)
WO (1)	WO1998013029A1 (cs)
ZA (1)	ZA978431B (cs)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030109503A1 (en) *	1995-06-06	2003-06-12	Smithkline Beecham P.L.C.	Pharmaceutical formulations comprising clavulanic acid alone or in combination with other beta-lactam antibiotics
SK17422000A3 (sk) *	1998-05-20	2001-09-11	The Liposome Company, Inc.	Kompozöcie ¬astöc
SE9802973D0 (sv) *	1998-09-03	1998-09-03	Astra Ab	Immediate release tablet
US20010055613A1 (en) *	1998-10-21	2001-12-27	Beth A. Burnside	Oral pulsed dose drug delivery system
MXPA01004381A (es) *	1998-11-02	2005-09-08	Elan Corp Plc	Composicion de multiparticulado de liberacion modificada.
US6294199B1 (en)	1999-04-13	2001-09-25	Beecham Pharmaceuticals (Pte) Limited	Method of treating a bacterial infection comprising administering amoxycillin
US6878386B1 (en)	1999-04-13	2005-04-12	Beecham Pharmaceuticals (Pte) Limited	Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate
US7250176B1 (en)	1999-04-13	2007-07-31	Beecham Pharmaceuticals (Pte) Limited	Method of treating a bacterial infection
IE990406A1 (en) *	1999-05-20	2000-12-27	Elan Corp Plc	Multiparticulate controlled release selective serotonin reuptake inhibitor formulations.
EP1064937A1 (en) *	1999-06-28	2001-01-03	Sanofi-Synthelabo	Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof
EP1074249A1 (en) *	1999-07-27	2001-02-07	Jagotec Ag	A pharmaceutical tablet system for releasing at least one active substance during a release period subsequent to a no-release period
US6592869B2 (en)	1999-08-24	2003-07-15	Teva Pharmaceutical Industries, Ltd.	Vaccine composition and method of using the same
IL148247A0 (en)	1999-08-24	2002-09-12	Teva Pharma	A vaccine composition and method of using the same
US6485746B1 (en)	2000-08-25	2002-11-26	Neurocrine Biosciences, Inc.	Controlled-release sedative-hypnotic compositions and methods related thereto
ATE241968T1 (de) *	1999-08-26	2003-06-15	Neurocrine Biosciences Inc	Sedativ hypnotische zusammensetzungen mit gesteuerter freisetzung und diesbezügliche verfahren
DE10012555A1 (de) *	2000-03-15	2001-09-20	Merck Patent Gmbh	Glucocorticoide in einer Modified Release-Formulierung
US6720005B1 (en) *	2000-07-07	2004-04-13	The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University	Coated, platform-generating tablet
US6756057B2 (en)	2000-10-12	2004-06-29	Beecham Pharmaceuticals (Pte) Limited	Amoxicillin and potassium clavulanate dosage form
WO2002030392A2 (en)	2000-10-12	2002-04-18	Beecham Pharmaceuticals (Pte) Limited	Formulation containing amoxicillin
US6913768B2 (en) *	2002-09-24	2005-07-05	Shire Laboratories, Inc.	Sustained release delivery of amphetamine salts
US20080220074A1 (en) *	2002-10-04	2008-09-11	Elan Corporation Plc	Gamma radiation sterilized nanoparticulate docetaxel compositions and methods of making same
US7772188B2 (en)	2003-01-28	2010-08-10	Ironwood Pharmaceuticals, Inc.	Methods and compositions for the treatment of gastrointestinal disorders
KR101192722B1 (ko) *	2003-04-24	2012-10-18	자고텍 아게	정해진 핵 위치를 가지는 서방성 정제
US20070148229A1 (en) *	2003-04-24	2007-06-28	Jagotec Ag	Tablet with coloured core
WO2005016318A1 (en) *	2003-08-08	2005-02-24	Biovail Laboratories Inc.	Modified-release tablet of bupropion hydrochloride
CA2544678C (en)	2003-11-05	2013-12-31	Sunesis Pharmaceuticals, Inc.	Modulators of cellular adhesion
DE602005025755D1 (de)	2004-06-04	2011-02-17	Teva Pharma	Irbesartan enthaltende pharmazeutische zusammensetzung
DE102004043863A1 (de)	2004-09-10	2006-03-16	Nitec Pharma Ag	Tabletten mit orts- und zeitgesteuerter Wirkstofffreisetzung im Gastrointestinum
GB0423964D0 (en) *	2004-10-28	2004-12-01	Jagotec Ag	Dosage form
WO2006063078A2 (en) *	2004-12-08	2006-06-15	Elan Corporation, Plc	Topiramate pharmaceuticals composition
AU2006235483B2 (en) *	2005-04-12	2010-11-25	Elan Pharma International Limited	Controlled release compositions comprising a cephalosporin for the treatment of a bacterial infection
DK2444079T3 (en)	2005-05-17	2017-01-30	Sarcode Bioscience Inc	Compositions and Methods for the Treatment of Eye Diseases
WO2007037790A2 (en) *	2005-06-08	2007-04-05	Elan Corporation, Plc	Modified release famciclovir compositions
CA2617051C (en)	2005-07-29	2013-12-17	Stichting Groningen Centre For Drug Research	Ph-controlled pulsatile delivery system, methods for preparation and use thereof
US20070036859A1 (en) *	2005-08-11	2007-02-15	Perry Ronald L	Sustained release antihistamine and decongestant composition
TWI274889B (en) *	2005-10-06	2007-03-01	Elan Microelectronics Corp	Resistive touch screen measurement system
US8187633B2 (en) *	2005-11-03	2012-05-29	Sun Pharma Advanced Research Company Limited	Controlled release coated tablets having prolonged gastric retention
RU2308941C1 (ru) *	2006-05-10	2007-10-27	Открытое акционерное общество "Московское производственное химико-фармацевтическое объединение им. Н.А. Семашко"	Твердая лекарственная форма, обладающая гистаминоподобным действием, и способ ее получения
SI2049123T1 (sl) *	2006-08-03	2013-04-30	Horizon Pharma Ag	Zdravljenje revmatoznih bolezni z zadrĹľanim sproĹˇÄŤanjem glukokortikoida
US20080081067A1 (en) *	2006-10-03	2008-04-03	Gupta Manishkumar	Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof
RU2356539C2 (ru) *	2006-12-28	2009-05-27	Закрытое Акционерное Общество "Канонфарма Продакшн"	Твердая лекарственная форма бетагистина дигидрохлорида и способ ее получения
US8969514B2 (en)	2007-06-04	2015-03-03	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX354786B (es)	2007-06-04	2018-03-21	Synergy Pharmaceuticals Inc	Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
WO2009021127A2 (en) *	2007-08-07	2009-02-12	Neurogen Corporation	Controlled released compositions
ES2830024T3 (es)	2007-10-19	2021-06-02	Novartis Ag	Composiciones y métodos para el tratamiento del edema macular
WO2009139817A2 (en)	2008-04-15	2009-11-19	Sarcode Corporation	Crystalline pharmaceutical and methods of preparation and use thereof
ES2522968T3 (es)	2008-06-04	2014-11-19	Synergy Pharmaceuticals Inc.	Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
AU2009270833B2 (en)	2008-07-16	2015-02-19	Bausch Health Ireland Limited	Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
TWI494108B (zh) *	2009-01-26	2015-08-01	Nitec Pharma Ag	糖皮質激素用以製備嚴重夜間氣喘用之於延遲釋放型的藥物之用途
NZ582836A (en) *	2009-01-30	2011-06-30	Nitec Pharma Ag	Delayed-release glucocorticoid treatment of rheumatoid arthritis by improving signs and symptoms, showing major or complete clinical response and by preventing from joint damage
WO2011050175A1 (en)	2009-10-21	2011-04-28	Sarcode Corporation	Crystalline pharmaceutical and methods of preparation and use thereof
EP2314296A1 (en) *	2009-10-22	2011-04-27	Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi	Orally Disintegrating Tablets of Betahistine
US9616097B2 (en)	2010-09-15	2017-04-11	Synergy Pharmaceuticals, Inc.	Formulations of guanylate cyclase C agonists and methods of use
WO2012071220A1 (en) *	2010-11-23	2012-05-31	Transcept Pharmaceuticals, Inc.	Compositions and methods for once-daily administration of a trilayer osmotic tablet
RU2453308C1 (ru) *	2010-12-20	2012-06-20	Государственное образовательное учреждение высшего профессионального образования "БАШКИРСКИЙ ГОСУДАРСТВЕННЫЙ МЕДИЦИНСКИЙ УНИВЕРСИТЕТ ФЕДЕРАЛЬНОГО АГЕНТСТВА ПО ЗДРАВООХРАНЕНИЮ И СОЦИАЛЬНОМУ РАЗВИТИЮ"	Драже с оксиметилурацилом и мебеверина гидрохлоридом для лечения функциональных заболеваний желудочно-кишечного тракта
KR102258769B1 (ko) *	2011-10-14	2021-06-01	지엘팜텍주식회사	장용소화효소제 및 그 제조방법
DE102012105528A1 (de)	2012-06-25	2014-01-02	Hennig Arzneimittel Gmbh & Co. Kg	Arzneiform zur Freisetzung von Wirkstoffen
KR20200108932A (ko)	2012-07-25	2020-09-21	에스에이알코드 바이오사이언스 인코포레이티드	Lfa-1 저해제 및 그의 다형체
WO2014131024A2 (en)	2013-02-25	2014-08-28	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase and their uses
AU2014235209B2 (en)	2013-03-15	2018-06-14	Bausch Health Ireland Limited	Guanylate cyclase receptor agonists combined with other drugs
AU2014235215A1 (en)	2013-03-15	2015-10-01	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase and their uses
JP6661531B2 (ja)	2013-10-10	2020-03-11	シナジーファーマシューティカルズインコーポレイテッド	オピオイド誘発性機能障害の治療に有用なグアニル酸シクラーゼのアゴニスト
HK1245079A1 (zh) *	2015-06-30	2018-08-24	纽拉德有限公司	新颖呼吸控制调节化合物以及其制备和使用方法
US10653744B2 (en)	2016-01-11	2020-05-19	Bausch Health Ireland Limited	Formulations and methods for treating ulcerative colitis
CN108836948B (zh) *	2018-06-11	2024-04-12	宁波西敦医药包衣科技有限公司	一种利用包衣技术实现营养素可控制释放的产品
RU2695135C1 (ru) *	2018-07-11	2019-07-22	Федеральное государственное унитарное предприятие "Научно-исследовательский институт гигиены, профпатологии и экологии человека" Федерального медико-биологического агентства	Двухуровневая микрогранулированная форма терапевтического пептида для перорального применения и способ ее получения
CN110403912A (zh) *	2019-09-04	2019-11-05	西安科力康医药科技有限公司	缓控释包衣粉

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH666405A5 (de) *	1985-06-24	1988-07-29	Ciba Geigy Ag	Feste, haltbare darreichungsformen mit elastischem filmueberzug.
GB8524001D0 (en) *	1985-09-30	1985-11-06	Glaxo Group Ltd	Pharmaceutical composition
US5122384A (en) *	1989-05-05	1992-06-16	Kv Pharmaceutical Company	Oral once-per-day organic nitrate formulation which does not induce tolerance
US5133974A (en) *	1989-05-05	1992-07-28	Kv Pharmaceutical Company	Extended release pharmaceutical formulations
US5032405A (en) *	1989-09-27	1991-07-16	Warner-Lambert Company	Oral pharmaceutical composition for acid sensitive proteinaceous agents
FR2655266B1 (fr) *	1989-12-05	1992-04-03	Smith Kline French Lab	Compositions pharmaceutiques a base de cimetidine.
US5229131A (en) *	1990-02-05	1993-07-20	University Of Michigan	Pulsatile drug delivery system
US5158777A (en) *	1990-02-16	1992-10-27	E. R. Squibb & Sons, Inc.	Captopril formulation providing increased duration of activity
GB9104854D0 (en) *	1991-03-07	1991-04-17	Reckitt & Colmann Prod Ltd	Sustained release compositions
US5286497A (en)	1991-05-20	1994-02-15	Carderm Capital L.P.	Diltiazem formulation
HU227530B1 (en) *	1991-11-22	2011-07-28	Warner Chilcott Company	Delayed-release compositions containing risedronate and process for their production
AU3949093A (en) *	1992-03-31	1993-11-08	Benzon Pharma A/S	A pharmaceutical formulation
US5500227A (en) *	1993-11-23	1996-03-19	Euro-Celtique, S.A.	Immediate release tablet cores of insoluble drugs having sustained-release coating
HUT77530A (hu) *	1994-05-06	1998-05-28	Pfizer Inc.	Azitromicint tartalmazó, szabályozott hatóanyag-felszabadítású dózisformák

1997
- 1997-09-16 HR HR96202651,4A patent/HRP970493A2/hr not_active Application Discontinuation
- 1997-09-18 KR KR10-1999-7002380A patent/KR100501966B1/ko not_active Expired - Fee Related
- 1997-09-18 DE DE69710756T patent/DE69710756T2/de not_active Expired - Lifetime
- 1997-09-18 NZ NZ334463A patent/NZ334463A/xx not_active IP Right Cessation
- 1997-09-18 CZ CZ1999995A patent/CZ294641B6/cs not_active IP Right Cessation
- 1997-09-18 TR TR1999/00641T patent/TR199900641T2/xx unknown
- 1997-09-18 IL IL12856597A patent/IL128565A/xx not_active IP Right Cessation
- 1997-09-18 JP JP51526398A patent/JP4947824B2/ja not_active Expired - Fee Related
- 1997-09-18 DK DK97943895T patent/DK0939623T3/da active
- 1997-09-18 PT PT97943895T patent/PT939623E/pt unknown
- 1997-09-18 BR BR9711303A patent/BR9711303A/pt not_active Application Discontinuation
- 1997-09-18 RU RU99108461/14A patent/RU2193395C2/ru not_active IP Right Cessation
- 1997-09-18 ID IDW990114A patent/ID22039A/id unknown
- 1997-09-18 ZA ZA9708431A patent/ZA978431B/xx unknown
- 1997-09-18 AT AT97943895T patent/ATE213627T1/de active
- 1997-09-18 UA UA99042314A patent/UA72182C2/uk unknown
- 1997-09-18 AU AU45570/97A patent/AU717711B2/en not_active Ceased
- 1997-09-18 CA CA002263921A patent/CA2263921C/en not_active Expired - Fee Related
- 1997-09-18 HU HU9904121A patent/HU226693B1/hu not_active IP Right Cessation
- 1997-09-18 SK SK376-99A patent/SK284263B6/sk not_active IP Right Cessation
- 1997-09-18 WO PCT/EP1997/005234 patent/WO1998013029A1/en not_active Ceased
- 1997-09-18 ES ES97943895T patent/ES2172003T3/es not_active Expired - Lifetime
- 1997-09-18 CN CNB971981671A patent/CN1161110C/zh not_active Expired - Fee Related
- 1997-09-18 PL PL97332245A patent/PL189016B1/pl not_active IP Right Cessation
- 1997-09-18 EP EP97943895A patent/EP0939623B1/en not_active Expired - Lifetime
- 1997-09-19 US US08/934,196 patent/US6183780B1/en not_active Expired - Lifetime
- 1997-09-21 JO JO19972066A patent/JO2066B1/en active
- 1997-09-22 DZ DZ970164A patent/DZ2314A1/xx active
1999
- 1999-03-22 NO NO19991385A patent/NO325763B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
CZ99599A3 (cs)	1999-06-16
HUP9904121A2 (hu)	2000-04-28
CZ294641B6 (cs)	2005-02-16
US6183780B1 (en)	2001-02-06
BR9711303A (pt)	1999-08-17
DE69710756D1 (de)	2002-04-04
SK284263B6 (sk)	2004-12-01
PL332245A1 (en)	1999-08-30
HU226693B1 (en)	2009-06-29
AU4557097A (en)	1998-04-17
CA2263921C (en)	2006-05-23
AU717711B2 (en)	2000-03-30
PT939623E (pt)	2002-08-30
NZ334463A (en)	2000-12-22
PL189016B1 (pl)	2005-06-30
DK0939623T3 (da)	2002-06-10
IL128565A (en)	2003-02-12
ZA978431B (en)	1998-03-26
CN1161110C (zh)	2004-08-11
CN1231601A (zh)	1999-10-13
ES2172003T3 (es)	2002-09-16
ID22039A (id)	1999-08-26
HRP970493A2 (en)	1998-08-31
NO325763B1 (no)	2008-07-14
SK37699A3 (en)	1999-08-06
NO991385L (no)	1999-05-25
UA72182C2 (en)	2005-02-15
JO2066B1 (en)	2000-05-21
JP4947824B2 (ja)	2012-06-06
JP2001500885A (ja)	2001-01-23
EP0939623A1 (en)	1999-09-08
KR20010029536A (ko)	2001-04-06
KR100501966B1 (ko)	2005-07-20
IL128565A0 (en)	2000-01-31
WO1998013029A1 (en)	1998-04-02
CA2263921A1 (en)	1998-04-02
RU2193395C2 (ru)	2002-11-27
DE69710756T2 (de)	2002-10-24
EP0939623B1 (en)	2002-02-27
TR199900641T2 (xx)	1999-07-21
ATE213627T1 (de)	2002-03-15
HK1019852A1 (en)	2000-03-03
HUP9904121A3 (en)	2004-10-28
NO991385D0 (no)	1999-03-22

Publication	Publication Date	Title
DZ2314A1 (fr)	2002-12-28	Formulation pour administration par voie orale à libération immédiate retardée et procédé pour sa préparation.
RU2159761C2 (ru)	2000-11-27	Замещенные 4-биарилмасляные или 5-биарилпентановые кислоты или их производные, способы их получения, фармацевтическая композиция и способ лечения
DE69532088D1 (de)	2003-12-11	Verfahren zur steigerung der immunogenizität, erhaltenes produkt und arzneimittel
ATE246496T1 (de)	2003-08-15	Spheroide, verfahren zu ihrer herstellung und diese enthaltende arzneiformen
TNSN98068A1 (fr)	2005-03-15	Composition pharmaceutique d'omeprazole
GB2364304A (en)	2002-01-23	Novel tricyclic compounds and their use in medicine process for their preparation and pharmaceutical compositions containing them
ATE74513T1 (de)	1992-04-15	Stabilisierte arzneistoffe, verfahren zu ihrer herstellung sowie stabile arzneizubereitungen.
DE69104991D1 (de)	1994-12-08	Mometason-furoate-monohydrat, verfahren zu seiner herstellung und das enthaltende pharmazeutische zusammensetzungen.
ES8401009A1 (es)	1983-12-16	Procedimiento para la preparacion de 2-(p-isobutil-fenil)propionato de 2-hidroxi-3-(o-metoxi-fenoxi)propilo.
ATE1288T1 (de)	1982-07-15	Amino-pyrimidin-carbanilide, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel.
DE69207799D1 (de)	1996-03-07	Pharmazeutische Zubereitung mit verzögerter Wirkstoffreigabe und Verfahren zur Herstellung derselben
ATE217525T1 (de)	2002-06-15	Tiagabin enthaltende spheroide, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
BR9809234A (pt)	2000-06-27	Composto, composição farmacêutica, uso de um composto, processos para tratar ou prevenir doenças do sistema endocrinológico, para fabricar um medicamento, para preparar um composto e um conjunto, conjunto, e, uso do mesmo.
ATE48137T1 (de)	1989-12-15	Neue benzodipyrrole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel.
EP0268223A3 (de)	1990-03-28	Optisch aktive Gyrasehemmer, ihre Herstellung und Verwendung als Antibiotika
DE69714856D1 (de)	2002-09-26	Pharmazeutische zusammensetzung enthaltend einen embryonalen extrakt und verfahren zu ihrer herstellung
ATE56707T1 (de)	1990-10-15	Imidazolverbindungen, verfahren zu deren herstellung und deren pharmazeutische zusammensetzungen.
DE59108433D1 (de)	1997-02-06	Phenylethanolamine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE69516706D1 (de)	2000-06-08	Bis-2-aminopyridine, verfahren zu ihrer herstelung und ihre verwendung zur bekämpfung von parasitosen
ATE69809T1 (de)	1991-12-15	Leukotrienantagonisten, verfahren zu ihrer herstellung, ihre anwendung zur behandlung von krankheiten.
DE59504643D1 (de)	1999-02-04	Neue phosphanoxide, verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel
ATE53024T1 (de)	1990-06-15	Biologisch aktive substanz, girolline genannt, extrahiert aus dem schwamm pseudaxinyssa cantharella, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
ATE13181T1 (de)	1985-05-15	Pyridazinonimine und ihre physiologisch vertraeglichen saeureadditionssalze, verfahren zu ihrer herstellung und diese verbindungen enthaltende therapeutische mittel.
ECSP951622A (es)	1997-06-11	Compuestos quimicos
ES481311A1 (es)	1979-11-16	Procedimiento para la preparacion de un 2,3-dihidro-2-metil-3-2-(dimetilamino)-propil-fenil-1h-indol-1-carboxaldehido racemico.